Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed classical Hodgkin's lymphoma~  * No lymphocyte-predominant Hodgkin's lymphoma~ * Fine-needle biopsy not sufficient~* No prior treatment for Hodgkin's lymphoma except for recommended pre-phase therapy for a large mediastinal tumor~PATIENT CHARACTERISTICS:~* No known hypersensitivity or contraindication to study drugs~* No other current malignancy~* No severe concurrent disease (e.g., immune deficiency syndrome)~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment~* No known HIV positivity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy or radiotherapy~* At least 30 days since prior and no other concurrent investigational drugs or participation in another investigational trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- COPP (Type: ACTIVE_COMPARATOR): procarbazine-containing consolidation chemotherapy arm
- COPDAC (Type: EXPERIMENTAL): procarbazine-free consolidation chemotherapy arm

Based on this trial design, predict the completion outcome and termination type (if applicable).